Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

Next Previous
Trial Profile

Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Fexofenadine; Paracetamol
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use

Most Recent Events

  • 06 Jul 2022 Status changed from active, no longer recruiting to completed.
  • 09 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Jun 2022.
  • 09 Mar 2022 Planned primary completion date changed from 1 Dec 2021 to 15 Apr 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top